Friob MC et al. |
A combined HPLC-ELISA evaluation of FK 506 in transplant patients. |
1991 |
Transplant. Proc. |
pmid:1721265
|
Machida M et al. |
Effect of temperature and hematocrit on plasma concentration of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721266
|
Kawauchi M et al. |
Plasma level of FK 506 in newborn goats and infant baboons. |
1991 |
Transplant. Proc. |
pmid:1721267
|
Iwasaki K et al. |
Pharmacokinetic study of FK 506 in the rat. |
1991 |
Transplant. Proc. |
pmid:1721268
|
O'Neill EA et al. |
The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. |
1991 |
Transplant. Proc. |
pmid:1721298
|
Nelson PA et al. |
Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. |
1991 |
Transplant. Proc. |
pmid:1721299
|
Dumont FJ et al. |
Up-regulation of gene expression by FK 506. |
1991 |
Transplant. Proc. |
pmid:1721300
|
Rao P et al. |
Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. |
1991 |
Transplant. Proc. |
pmid:1721301
|
Ishibashi M et al. |
Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. |
1991 |
Transplant. Proc. |
pmid:1721330
|
Kawauchi M et al. |
Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. |
1991 |
Transplant. Proc. |
pmid:1721331
|
Borg AJ and Kumagai M |
FK 506 and xenogeneic human anti-porcine cellular reactivity. |
1991 |
Transplant. Proc. |
pmid:1721332
|
Fung J et al. |
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721333
|
Shapiro R et al. |
FK 506 in clinical kidney transplantation. |
1991 |
Transplant. Proc. |
pmid:1721361
|
Todo S et al. |
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. |
1991 |
Transplant. Proc. |
pmid:1703340
|
McCauley J et al. |
Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. |
1991 |
Transplant. Proc. |
pmid:1721362
|
Zeevi A et al. |
Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. |
1991 |
Transplant. Proc. |
pmid:1703341
|
|
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. |
1991 |
Transplant. Proc. |
pmid:1721363
|
van Hoek B et al. |
Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. |
1991 |
Transplant. Proc. |
pmid:1703343
|
Jensen CW et al. |
Pediatric renal transplantation under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1721364
|
McCauley J et al. |
The question of FK 506 nephrotoxicity after liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1703344
|
Scantlebury V et al. |
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. |
1991 |
Transplant. Proc. |
pmid:1721395
|
Carroll PB et al. |
FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. |
1991 |
Transplant. Proc. |
pmid:1721396
|
Freise CE et al. |
Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. |
1991 |
Transplant. Proc. |
pmid:1721397
|
Eidelman BH et al. |
Neurologic complications of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721398
|
Goebl MG |
The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. |
1991 |
Cell |
pmid:1706222
|
Langrehr JM et al. |
Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. |
1991 |
Transplant. Proc. |
pmid:1721425
|
de Paulis A et al. |
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. |
1991 |
J. Immunol. |
pmid:1706398
|
Takeda Y et al. |
Effect of FK 506 on the survival of rat small bowel allografts. |
1991 |
Transplant. Proc. |
pmid:1721426
|
Griffiths EJ and Halestrap AP |
Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. |
1991 |
Biochem. J. |
pmid:1706598
|
Fukuzawa M et al. |
Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. |
1991 |
Transplant. Proc. |
pmid:1721427
|
Ogasa N et al. |
Effect of FK 506 on growth of transplanted newborn rat intestine. |
1991 |
Transplant. Proc. |
pmid:1721428
|
Hultsch T et al. |
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1712484
|
Roat MI et al. |
Treatment of Cogan's syndrome with FK 506: a case report. |
1991 |
Transplant. Proc. |
pmid:1721457
|
Miyahara H et al. |
Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. |
1991 |
Clin. Immunol. Immunopathol. |
pmid:1712688
|
Carroll PB et al. |
The use of FK 506 in new-onset type I diabetes in man. |
1991 |
Transplant. Proc. |
pmid:1721458
|
McAlpine JB et al. |
Revised NMR assignments for rapamycin. |
1991 |
J. Antibiot. |
pmid:1712766
|
McCauley J et al. |
FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. |
1991 |
Transplant. Proc. |
pmid:1721459
|
Carrieri G et al. |
Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. |
1991 |
Transplant. Proc. |
pmid:1721460
|
McWhinnie DL and Morris PJ |
Combination drug therapies for immunosuppression in transplantation. |
1991 |
Ann. Acad. Med. Singap. |
pmid:1724724
|
Pourtier-Manzanedo A et al. |
FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. |
1991 |
Anticancer Drugs |
pmid:1724925
|
Thomson AW |
The immunosuppressive macrolides FK-506 and rapamycin. |
1991 |
Immunol. Lett. |
pmid:1717376
|
Takaya S et al. |
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. |
1991 |
Transplant. Proc. |
pmid:1703691
|
Nakahama H et al. |
Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. |
1991 |
J. Cardiovasc. Pharmacol. |
pmid:1725322
|
Steeves M et al. |
In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. |
1991 |
J. Pharm. Pharmacol. |
pmid:1717676
|
Hildebrandt A et al. |
FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. |
1991 |
Transplant. Proc. |
pmid:1703694
|
Romanowski P et al. |
[Synthetic immunomodulators designed on the basis of natural products of microorganisms]. |
1991 |
Postepy Biochem. |
pmid:1725924
|
|
Unmasking immunosuppression. |
1991 |
Lancet |
pmid:1717800
|
Ericzon BG et al. |
Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. |
1991 |
Transplant. Proc. |
pmid:1703695
|
Markus PM et al. |
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. |
1991 |
Transplantation |
pmid:1718063
|
Kumano K et al. |
FK 506-induced nephrotoxicity in rats. |
1991 |
Transplant. Proc. |
pmid:1703696
|